Novel clinical trial designs and HIV-1 RNA assessments with end-point and real-time PCR tests.

[1]  A. Phillips,et al.  Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Liegler,et al.  Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Bryan R Cobb,et al.  Evolution in the sensitivity of quantitative HIV-1 viral load tests. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  C. Delaugerre,et al.  Comparative RNA Quantification of HIV-1 Group M and Non-M With the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR Assays , 2011, Journal of acquired immune deficiency syndromes.

[5]  A. Kelleher,et al.  Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  R. Écochard,et al.  HIV-1 Load Comparison Using Four Commercial Real-Time Assays , 2010, Journal of Clinical Microbiology.